微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 37.01% | 0.53% | 2% | 97/159 | -2.82% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 36.28% | -1.18% | -2.24% | 103/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 37.12% | 2.44% | 8.76% | 100/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 34.13% | -12.75% | -7.3% | 112/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 36.81% | -8.94% | 0.26% | 105/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 36.72% | -11.9% | 1.33% | 105/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 36.23% | -6.5% | -7.36% | 105/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 39.11% | -3.41% | -3.25% | 107/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 40.43% | 0.89% | -3% | 104/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 41.68% | 5.49% | 7.54% | 101/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 38.75% | 3.09% | -4.3% | 102/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 40.49% | 6% | 1.06% | 102/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 40.07% | 2.23% | 1.43% | 97/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 39.51% | -2.24% | 5.09% | 102/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 37.59% | -0.36% | -1.6% | 102/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 38.2% | -6.74% | -2.54% | 110/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 39.2% | -8.42% | -3.01% | 95/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 40.41% | -1.31% | 7.11% | 99/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 37.73% | -0.21% | -7.89% | 90/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 40.96% | -11.97% | -4.29% | 103/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 42.8% | -6.17% | 4.51% | 84/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 40.95% | -4.79% | 8.3% | 94/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 37.81% | -7.73% | -18.74% | 84/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 46.53% | 14.63% | 2.02% | 85/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 45.61% | 17.08% | 6.05% | 67/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 43.01% | 14.2% | 4.96% | 76/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 40.97% | 15.76% | 0.94% | 74/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 40.59% | 27.22% | 4.19% | 92/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 38.96% | 25.03% | 3.45% | 75/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 37.66% | 23.55% | 6.39% | 80/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 35.4% | 26.48% | 10.94% | 77/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 31.91% | -3.3% | 2.4% | 93/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 31.16% | -9.94% | 2.22% | 75/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 30.48% | -9% | 8.91% | 79/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 27.99% | -16.65% | -15.18% | 67/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 32.99% | -4.53% | -4.64% | 83/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 34.6% | 1.59% | 3.29% | 54/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 33.5% | 6.85% | -0.24% | 65/159 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 33.58% | 11.17% | -2.85% | 53/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 34.56% | 13.4% | 1.47% | 72/159 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 34.06% | 15.24% | 8.64% | 52/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 31.35% | 15.45% | 3.79% | 58/159 | 45% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 30.2% | 18.2% | -0.9% | 51/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |